Biotech company Alnylam Pharmaceuticals conceded defeat for now in a lawsuit against Pfizer and BioNTech over technology in ...

The European Court of Justice Wednesday ruled there was no plausible reason to block the New York Times from getting European ...

A case against one of the major COVID-19 vaccine providers filed by the Kansas Attorney General will be heard at the state ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...

Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

Patients taking tofacitinib (Xeljanz) in the drug's late-stage and post-marketing studies were more likely than those on ...

The EU Court found the head of the European Commission, Ursula von der Leyen, responsible for concealing information about ...

The EU’s general court has dismissed the European Commission’s refusal to disclose text messages its president Ursula von der ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...